CAR T-immunotherapy lisocabtagene maraleucel (Breyanzi®) was approved for treatment of adults with large B-cell lymphoma (LBCL), the most common type of lymphoma, whose cancer has returned or worsened within 12 months of first-line chemotherapy. When used earlier in treatment, CAR-T can offer patients with LBCL a superior long-term remission rate and potentially the hope of a cure for some patients.
No comments:
Post a Comment